

### In the Claims

Please cancel claims 3 and 4.

1. (twice amended) A method for diagnosing glaucoma in a person, said method comprising the steps:

- C 2
- (a) obtaining a biological sample from said person; and
  - (b) analyzing said sample for expression of SEQ ID NO:2;

wherein aberrant expression of SEQ ID NO:2 or a defect in a GR gene encoding SEQ ID NO:2 as compared to SEQ ID NO:1 indicates a diagnosis of glaucoma.

5. (amended) A method for determining whether an agent is useful for treating glaucoma, said method comprising the steps:

- C 3
- (a) obtaining a composition comprising SEQ ID NO:1 or SEQ ID NO:2;
  - (b) admixing said composition with an agent; and

determining whether the agent interacts with SEQ ID NO:1 or alters the expression of SEQ ID NO:2.

## II. RESPONSE TO OFFICE ACTION

### A. Status of the Claims

The parent application is a Continuing Prosecution Application (CPA) under 37 C.F.R. § 1.53(d) based on parent application No. 09/308,295. Claims 1-5 were filed with the case. In the parent application, the claims were under final rejection as being indefinite and lacking enablement. These rejections are addressed herein.